Article
Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status.
Journal of experimental therapeutics & oncology - 1 Jan 2010
Oshita Fumihiro, Miyagi Yohei, Honda Takeshi, Murakami Shuji, Kondo Tetsuro, Saito Haruhiro, Noda Kazumasa, Yokose Tomoyuki, Kameda Yoichi, Sakuma Yuji, Obata Masato, Yamada Kouzo
Abstract excerpt
We prospectively investigated the outcome of personalized second-line treatment based on epidermal growth factor receptor (EGFR) gene status in previously treated patients with advanced non-small cell lung cancer (NSCLC). EGFR gene status was evaluable by LH-mobility shift assay in registered patients. Gefitinib (Gef) treatment was recommended if the patients had EGFR mutation (mEGFR). EGFR gene status was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.